Arvinas, Inc. – NASDAQ:ARVN
Arvinas stock price today
$7.14
-11.86
-62.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Arvinas stock price monthly change
-34.19%
month
Arvinas stock price quarterly change
-34.19%
quarter
Arvinas stock price yearly change
-55.12%
year
Arvinas key metrics
Market Cap | 1.23B |
Enterprise value | 1.34B |
P/E | -5.14 |
EV/Sales | 10.22 |
EV/EBITDA | -5.56 |
Price/Sales | 10.80 |
Price/Book | 2.51 |
PEG ratio | 0.13 |
EPS | -5.93 |
Revenue | 71.3M |
EBITDA | -393.7M |
Income | -354.8M |
Revenue Q/Q | -22.15% |
Revenue Y/Y | -46.02% |
Profit margin | -214.99% |
Oper. margin | -200.38% |
Gross margin | 0% |
EBIT margin | -200.38% |
EBITDA margin | -552.17% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArvinas stock price history
Arvinas stock forecast
Arvinas financial statements
Average Price Target
$55
Potential upside: 670.30%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 54.5M | -66.6M | -122.2% |
|---|---|---|---|
| Sep 2023 | 34.6M | -64M | -184.97% |
| Dec 2023 | -43.1M | -154.8M | 359.16% |
| Mar 2024 | 25.3M | -69.4M | -274.31% |
| Jun 2023 | 1083500000 | 619.9M | 57.21% |
|---|---|---|---|
| Sep 2023 | 1058300000 | 601.1M | 56.8% |
| Dec 2023 | 1304600000 | 644.6M | 49.41% |
| Mar 2024 | 1212600000 | 602.9M | 49.72% |
| Jun 2023 | -88.7M | 48.6M | 500K |
|---|---|---|---|
| Sep 2023 | -84.8M | 70M | 37.9M |
| Dec 2023 | -83.1M | -53.7M | 334.8M |
| Mar 2024 | -97.5M | -127.8M | 1.6M |
Arvinas alternative data
| Aug 2023 | 415 |
|---|---|
| Sep 2023 | 415 |
| Oct 2023 | 415 |
| Nov 2023 | 415 |
| Dec 2023 | 415 |
| Jan 2024 | 415 |
| Feb 2024 | 415 |
| Mar 2024 | 445 |
| Apr 2024 | 445 |
| May 2024 | 445 |
| Jun 2024 | 445 |
| Jul 2024 | 445 |
Arvinas other data
92.39%
+2.26%
of ARVN is owned by hedge funds
167
-30
46.19M
+1.30M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 1324 |
| Feb 2024 | 0 | 10298 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HOUSTON JOHN G director, officer.. | Common Stock | 5,196 | $47.05 | $244,472 | ||
Sale | CASSIDY SEAN A officer: Chief Financial Officer | Common Stock | 1,702 | $47.05 | $80,079 | ||
Sale | PECK RONALD officer: Chief Medical Officer | Common Stock | 1,699 | $47.05 | $79,938 | ||
Sale | TAYLOR IAN officer: Chief Sc.. | Common Stock | 1,701 | $47.05 | $80,032 | ||
Option | TAYLOR IAN officer: Chief Sc.. | Common Stock | 8,252 | $16 | $132,032 | ||
Option | TAYLOR IAN officer: Chief Sc.. | Stock Option (right to buy) | 0 | $16 | $0 | ||
Option | TAYLOR IAN officer: Chief Sc.. | Stock Option (right to buy) | 0 | $16 | $0 | ||
Option | PECK RONALD officer: Chief Medical Officer | Common Stock | 4,010 | N/A | N/A | ||
Sale | PECK RONALD officer: Chief Medical Officer | Common Stock | 1,324 | $24.39 | $32,288 | ||
Option | PECK RONALD officer: Chief Medical Officer | Restricted Stock Units | 4,010 | N/A | N/A |
| Patent |
|---|
Grant Filling date: 5 Aug 2016 Issue date: 15 Sep 2020 |
Grant Filling date: 18 Mar 2016 Issue date: 4 Aug 2020 |
Grant Utility: Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides Filling date: 22 Dec 2017 Issue date: 28 Jul 2020 |
Grant Utility: Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders Filling date: 1 Dec 2017 Issue date: 12 May 2020 |
Grant Filling date: 26 Jan 2018 Issue date: 31 Mar 2020 |
Application Filling date: 20 Sep 2019 Issue date: 26 Mar 2020 |
Grant Filling date: 11 Oct 2017 Issue date: 10 Mar 2020 |
| Insider | Compensation |
|---|---|
| Dr. John G. Houston Ph.D. (1960) Chief Executive Officer, Pres & Director | $1,020,000 |
| Dr. Ian Taylor Ph.D. (1963) Chief Scientific Officer | $657,700 |
Mr. Sean A. Cassidy CPA, M.B.A., CPA (1970) Chief Financial Officer & Treasurer | $617,000 |
Arvinas' Vepdegestrant: Why The Data May Not Hold Up
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
Arvinas: Positive Breast Cancer Data Leads To Other Developments
Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
Arvinas' Potential In Treating ER+, HER2- Breast Cancer
Arvinas: PROTAC Platform Shows Promise In Clinical Trials For Oncology Indications
Kymera: Data Derisks Platform, But I Will Wait For More
Verona Pharma: Breathing Deeply Could Bring Great Benefits
-
What's the price of Arvinas stock today?
One share of Arvinas stock can currently be purchased for approximately $7.14.
-
When is Arvinas's next earnings date?
Unfortunately, Arvinas's (ARVN) next earnings date is currently unknown.
-
Does Arvinas pay dividends?
No, Arvinas does not pay dividends.
-
How much money does Arvinas make?
Arvinas has a market capitalization of 1.23B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 40.26% to 78.5M US dollars.
-
What is Arvinas's stock symbol?
Arvinas, Inc. is traded on the NASDAQ under the ticker symbol "ARVN".
-
What is Arvinas's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arvinas?
Shares of Arvinas can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arvinas's key executives?
Arvinas's management team includes the following people:
- Dr. John G. Houston Ph.D. Chief Executive Officer, Pres & Director(age: 65, pay: $1,020,000)
- Dr. Ian Taylor Ph.D. Chief Scientific Officer(age: 62, pay: $657,700)
- Mr. Sean A. Cassidy CPA, M.B.A., CPA Chief Financial Officer & Treasurer(age: 55, pay: $617,000)
-
How many employees does Arvinas have?
As Jul 2024, Arvinas employs 445 workers.
-
When Arvinas went public?
Arvinas, Inc. is publicly traded company for more then 6 years since IPO on 27 Sep 2018.
-
What is Arvinas's official website?
The official website for Arvinas is arvinas.com.
-
Where are Arvinas's headquarters?
Arvinas is headquartered at 5 Science Park, New Haven, CT.
-
How can i contact Arvinas?
Arvinas's mailing address is 5 Science Park, New Haven, CT and company can be reached via phone at +20 3 5351456.
-
What is Arvinas stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Arvinas in the last 12 months, the avarage price target is $55. The average price target represents a 670.30% change from the last price of $7.14.
Arvinas company profile:
Arvinas, Inc.
arvinas.comExchange:
NASDAQ
Full time employees:
445
Industry:
Biotechnology
Sector:
Healthcare
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
5 Science Park
New Haven, CT 06511
New Haven, CT 06511
CIK: 0001655759
ISIN: US04335A1051
CUSIP: 04335A105
